
CVS Health (CVS) Stock Forecast & Price Target
CVS Health (CVS) Analyst Ratings
Bulls say
CVS Health's strong financial outlook is underscored by an increase in the adjusted EPS estimate for 2026 to $7.19, reflecting a robust growth rate of 17.3% from the revised 2025 EPS. The company's strategic partnerships, particularly with Novo, are expected to enhance the affordability and accessibility of GLP-1 medications, further attracting plan sponsors due to preferred formulary positions. Additionally, there is anticipated improvement in the medical loss ratio (MLR), projected to drop 100 basis points year-over-year to 90.3%, indicating effective cost management and favorable medical cost trends.
Bears say
CVS Health faces significant challenges that hinder its ability to achieve material earnings per share (EPS) growth, particularly due to headwinds in Medicare Advantage utilization. Current projections indicate that FY26 EPS could fall approximately 10% below estimates, compounded by the assumption of a valuation decline to 7.5x, a level consistent with historical troughs. Additionally, the company is exposed to a range of risks, including elevated cost trends, regulatory pressures related to Medicare funding, and competitive threats to its retail pharmacy business that further exacerbate its negative outlook.
This aggregate rating is based on analysts' research of CVS Health and is not a guaranteed prediction by Public.com or investment advice.
CVS Health (CVS) Analyst Forecast & Price Prediction
Start investing in CVS Health (CVS)
Order type
Buy in
Order amount
Est. shares
0 shares